Recent News

• 03.30.2026 - IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
• 03.19.2026 - IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
• 03.18.2026 - IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
• 02.26.2026 - Healing from within: Gut Health Strategies That May Slow Alzheimer’s progression
• 02.26.2026 - IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
• 02.24.2026 - IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
• 02.23.2026 - IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
• 02.17.2026 - IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
• 02.12.2026 - IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
• 02.10.2026 - IGC Pharma Announces Equity Research Update by Alliance Global Partners

Recent Filings

• 03.30.2026 - 8-K Current report
• 03.30.2026 - EX-99.1 EX-99.1
• 03.18.2026 - 10-KT Transition reports [Rule 13a-10 or 15d-10]
• 03.12.2026 - 8-K Current report
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities